Clinical Trials Logo
  1. Home
  2. Graft-versus-host Disease (GVHD)
  3. NCT04167514

Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone (BMT CTN 1705)

Graft Versus Host Disease (GVHD) Clinical Trial

Official title:
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 - Antitrypsin (AAT) Combined With Corticosteroids vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplant (BMT CTN 1705)

Clinical Trial Summary

Study CSL964_5001 will investigate the efficacy of AAT with corticosteroids compared with corticosteroids alone as first line therapy for patients with high-risk acute GVHD

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04167514
Study type Interventional
Source CSL Behring
Contact
Status Active, not recruiting
Phase Phase 3
Start date January 9, 2020
Completion date May 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT01463475 - University of Wisconsin hMSC Cell Bank: Bone Marrow Donor Protocol N/A
Terminated NCT02167451 - Maraviroc as GVHD Prophylaxis in Transplant Recipients Phase 1/Phase 2
Terminated NCT01324908 - Biomarkers in Predicting Response in Patients With Graft-Versus-Host Disease Undergoing Extracorporeal Photophoresis N/A